UBS AG - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 88 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS AG ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2014$2,635,000
-70.1%
11,135
-70.1%
0.00%
-71.4%
Q2 2014$8,805,000
+107.6%
37,212
+189.3%
0.01%
+75.0%
Q1 2014$4,242,000
+16215.4%
12,861
+3214.7%
0.00%
Q4 2013$26,000
+85.7%
388
+96.0%
0.00%
Q3 2013$14,0001980.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2013
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders